Search

Your search keyword '"Oudard, S."' showing total 501 results
Start Over Author "Oudard, S." Search Limiters Full Text
501 results on '"Oudard, S."'

5. OA15.05 Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC

Author

Roulleaux Dugage, M., primary, Gorria, T., additional, Rochand, A., additional, Garcin, L.-M., additional, Oudard, S., additional, Albarrán-Artahona, V., additional, Laguna, J.C., additional, Nalda, I., additional, Muñoz-Carrillo, F.J., additional, Aguilar, L., additional, Arcocha, A., additional, Lupinacci, L., additional, Teixidó, C., additional, Besse, B., additional, Mezquita, L., additional, and Auclin, E., additional

Published
2023
Full Text
View/download PDF

7. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)

Author

Daban, A, primary, Gonnin, C, additional, Phan, L, additional, Saldmann, A, additional, Granier, C, additional, Lillo-Lelouet, A, additional, Le Beller, C, additional, Pouchot, J, additional, Weiss, l, additional, Tartour, E, additional, Fabre, E, additional, Medioni, J, additional, Oudard, S, additional, Vano, YA, additional, Dragon-Durey, MA, additional, and Simonaggio, A., additional

Published
2023
Full Text
View/download PDF

9. IMvigor010: Updated analysis of Overall Survival (OS) by circulating tumour DNA (ctDNA) status in patients with post-operative Muscle-Invasive Urothelial Carcinoma (MIUC) treated with atezolizumab

Author

Powles, T., primary, June Assaf, Z., additional, Mariathasan, S., additional, Hussain, M., additional, Oudard, S., additional, Albers, P., additional, Castellano, D., additional, Nishiyama, H., additional, Daneshmand, S., additional, Grivas, P., additional, Sharma, S., additional, Sethi, H., additional, Aleshin, A., additional, Degaonkar, V., additional, Shi, Y., additional, Davarpanah, N., additional, Carter, C.A., additional, Bellmunt, J., additional, and Gschwend, J.E., additional

Published
2022
Full Text
View/download PDF

10. 1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial

Author

Colomba, E., primary, Carril Ajuria, L., additional, Dalban, C., additional, Derosa, L., additional, Alves Costa Silva, C., additional, Rassy, E., additional, Negrier, S., additional, Chevreau, C.M., additional, Gravis Mescam, G., additional, Oudard, S., additional, Laguerre, B., additional, Barthelemy, P., additional, Gross Goupil, M., additional, Geoffrois, L., additional, Thiery-Vuillemin, A., additional, Joly Lobbedez, F., additional, Ladoire, S., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2022
Full Text
View/download PDF

11. 1762P MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study

Author

Haberstich, M., primary, Pignot, G., additional, Rigaud, J., additional, Cancel, M., additional, Maillet, D., additional, Oudard, S., additional, Pouessel, D., additional, Serrate, C., additional, Campedel, L., additional, Dumont, C., additional, Borchiellini, D., additional, Barthelemy, P., additional, Boughalem, E., additional, Colomba, E., additional, Huillard, O., additional, Boyle, H.J., additional, Lefort, F., additional, Constans Schlurmann, F., additional, Audenet, F., additional, and Thibault, C., additional

Published
2022
Full Text
View/download PDF

12. 1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial

Author

Meylan, M., primary, Sun, C-M., additional, Elaidi, R-T., additional, Moreira, M., additional, Bougouin, A., additional, Verkarre, V., additional, Bennamoun, M., additional, Chevreau, C.M., additional, Borchiellini, D., additional, Barthelemy, P., additional, Pannier, D., additional, Maillet, D., additional, Gross Goupil, M., additional, Tournigand, C., additional, Braychenko, E., additional, Phan, L., additional, Oudard, S., additional, Fridman, W-H., additional, Sautes-Fridman, C., additional, and Vano, Y-A., additional

Published
2022
Full Text
View/download PDF

13. 544P Feasibility of two different first-line carboplatin plus paclitaxel regimens in elderly women with ovarian cancer: A retrospective study

Author

Delanoy, N., primary, Ashton, E., additional, Mebarki, S., additional, Gisselbrecht, M., additional, Nicaise, B., additional, Azais, H., additional, Koual, M., additional, Mongardon, A-S. Bats, additional, Fournier, L., additional, Le Frère-Belda, M-A., additional, Medioni, J., additional, Paillaud, E., additional, and Oudard, S., additional

Published
2022
Full Text
View/download PDF

15. 1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial

Author

Oudard, S., primary, Beuzeboc, P., additional, Voog, E., additional, Barthelemy, P., additional, Thiery-Vuillemin, A., additional, Bennamoun, M., additional, Hasbini, A., additional, Aldabbagh, K., additional, Saldana, C., additional, Sevin, E., additional, Amela, Y.E., additional, Von Amsberg, G., additional, Houede, N., additional, Besson, D., additional, Feyerabend, S., additional, Boegemann, M., additional, Pfister, D., additional, Schostak, M., additional, Huillard, O., additional, and Helissey, C., additional

Published
2022
Full Text
View/download PDF

16. LBA69 Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study

Author

Srinivasan, R., primary, Iliopoulos, O., additional, Rathmell, W.K., additional, Narayan, V., additional, Maughan, B.L., additional, Oudard, S., additional, Else, T., additional, Maranchie, J.K., additional, Welsh, S.J., additional, Iversen, A.B. Bøndergaard, additional, Chen, K., additional, Perini, R.F., additional, Liu, Y., additional, Linehan, W.M., additional, and Jonasch, E., additional

Published
2022
Full Text
View/download PDF

18. A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer

Author

Agarwal, N, Azad, A, Carles, J, Chowdhury, S, McGregor, B, Merseburger, AS, Oudard, S, Saad, F, Soares, A, Benzaghou, F, Kerloeguen, Y, Kimura, A, Mohamed, N, Panneerselvam, A, Wang, F, Pal, S, Agarwal, N, Azad, A, Carles, J, Chowdhury, S, McGregor, B, Merseburger, AS, Oudard, S, Saad, F, Soares, A, Benzaghou, F, Kerloeguen, Y, Kimura, A, Mohamed, N, Panneerselvam, A, Wang, F, and Pal, S

Abstract

Cabozantinib inhibits multiple receptor tyrosine kinases, including the TAM kinase family, and may enhance response to immune checkpoint inhibitors. One cohort of the ongoing phase Ib COSMIC-021 study (NCT03170960) evaluating cabozantinib plus the PD-L1 inhibitor atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed in soft tissue on/after enzalutamide and/or abiraterone treatment for metastatic disease has shown promising efficacy. Here, we describe the rationale and design of a phase III trial of cabozantinib plus atezolizumab versus a second novel hormone therapy (NHT) in patients who have previously received an NHT for mCRPC, metastatic castration-sensitive PC or nonmetastatic CRPC and have measurable visceral disease and/or extrapelvic adenopathy - a population with a significant unmet need for treatment options. Trial Registration Clinical Trial Registration: NCT04446117 (ClinicalTrials.gov) Registered on 24 June 2020.

Published
2022

19. Непрямое сравнение эффективности и безопасности апалутамида и даролутамида для лечения неметастатического кастрационно-резистентного рака предстательной железы по результатам двух независимых исследований с поправкой на разницу между популяциями пациентов

Author

Chowdhury, Simon, Oudard, S., Uemura, H., Joniau, S., Dearden, L., Capone, C., van Sanden, S., Diels, J., and Hadaschik, Boris

Subjects
Science & Technology, ENZALUTAMIDE, Oncology, Nephrology, Urology, NETWORK METAANALYSIS, Medizin, MANAGEMENT, SURVIVAL, Radiology, Nuclear Medicine and imaging, Surgery, MEN, Life Sciences & Biomedicine
Abstract

ispartof: ONKOUROLOGIYA vol:18 issue:1 pages:77-89 status: published

Published
2022

26. 73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis

Author

Yu, E., primary, Piulats, J.M., additional, Gravis, G., additional, Fong, P., additional, Todenhöfer, T., additional, Laguerre, B., additional, Arranz, J., additional, Oudard, S., additional, Massard, C., additional, Stoeckle, M., additional, Nordquist, L.T., additional, Carles, J., additional, Huang, M., additional, Li, Y., additional, Qiu, P., additional, Poehlein, C.H., additional, Schloss, C., additional, and de Bono, J., additional

Published
2021
Full Text
View/download PDF

28. 612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

Author

Yu, E., primary, Piulats, J.M., additional, Gravis, G., additional, Fong, P.C.C., additional, Todenhöfer, T., additional, Laguerre, B., additional, Arranz Arija, J.A., additional, Oudard, S., additional, Massard, C., additional, Stoeckle, M., additional, Nordquist, L.T., additional, Carles, J., additional, Kolinsky, M.P., additional, Augustin, M., additional, Gurney, H., additional, Tafreshi, A., additional, Li, X.T., additional, Poehlein, C.H., additional, Schloss, C., additional, and de Bono, J.S., additional

Published
2021
Full Text
View/download PDF

29. 618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN

Author

Shen, J., primary, Chowdhury, S., additional, Agarwal, N., additional, Karsh, L.I., additional, Oudard, S., additional, Gartrell, B.A., additional, Feyerabend, S., additional, Saad, F., additional, Pieczonka, C.M., additional, Chi, K.N., additional, Brookman-May, S.D., additional, Rooney, B., additional, Bhaumik, A., additional, Londhe, A., additional, McCarthy, S.A., additional, Bevans, K.B., additional, Mundle, S.D., additional, Small, E.J., additional, Smith, M.R., additional, and Graff, J.N., additional

Published
2021
Full Text
View/download PDF

32. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA

Author

Sumanasuriya, S., Seed, G., Parr, H., Christova, R., Pope, L., Bertan, C., Bianchini, D., Rescigno, P., Figueiredo, I., Goodall, J., Fowler, G., Flohr, P., Mehra, N., Neeb, A., Rekowski, J., Eisenberger, M., Sartor, O., Oudard, S., Geffriaud-Ricouard, C., Ozatilgan, A., Chadjaa, M., Macé, S., Lord, C., Baxter, J., Pettitt, S., Lambros, M., Sharp, A., Mateo, J., Carreira, S., Yuan, W., Bono, J.S. de, Sumanasuriya, S., Seed, G., Parr, H., Christova, R., Pope, L., Bertan, C., Bianchini, D., Rescigno, P., Figueiredo, I., Goodall, J., Fowler, G., Flohr, P., Mehra, N., Neeb, A., Rekowski, J., Eisenberger, M., Sartor, O., Oudard, S., Geffriaud-Ricouard, C., Ozatilgan, A., Chadjaa, M., Macé, S., Lord, C., Baxter, J., Pettitt, S., Lambros, M., Sharp, A., Mateo, J., Carreira, S., Yuan, W., and Bono, J.S. de

Abstract

Contains fulltext : 235284.pdf (Publisher’s version ) (Open Access), BACKGROUND: Better blood tests to elucidate the behaviour of metastatic castration-resistant prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell-free DNA (cfDNA) comprises normal and circulating tumour DNA (ctDNA). Low-pass whole-genome sequencing (lpWGS) of ctDNA can provide information on mCRPC behaviour. OBJECTIVE: To validate and clinically qualify plasma lpWGS for mCRPC. DESIGN, SETTING, AND PARTICIPANTS: Plasma lpWGS data were obtained for mCRPC patients consenting to optional substudies of two prospective phase 3 trials (FIRSTANA and PROSELICA). In FIRSTANA, chemotherapy-naïve patients were randomised to treatment with docetaxel (75 mg/m(2)) or cabazitaxel (20 or 25 mg/m(2)). In PROSELICA, patients previously treated with docetaxel were randomised to 20 or 25 mg/m(2) cabazitaxel. lpWGS data were generated from 540 samples from 188 mCRPC patients acquired at four different time points (screening, cycle 1, cycle 4, and end of study). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: lpWGS data for ctDNA were evaluated for prognostic, response, and tumour genomic measures. Associations with response and survival data were determined for tumour fraction. Genomic biomarkers including large-scale transition (LST) scores were explored in the context of prior treatments. RESULTS AND LIMITATIONS: Plasma tumour fraction was prognostic for overall survival in univariable and stratified multivariable analyses (hazard ratio 1.75, 95% confidence interval 1.08-2.85; p = 0.024) and offered added value compared to existing biomarkers (C index 0.722 vs 0.709; p = 0.021). Longitudinal changes were associated with drug response. PROSELICA samples were enriched for LSTs (p = 0.029) indicating genomic instability, and this enrichment was associated with prior abiraterone and enzalutamide treatment but not taxane or radiation therapy. Higher LSTs were correlated with losses of RB1/RNASEH2B, independent of BRCA2 loss. CONCLUSIONS: Plasma lpWGS of ctD

Published
2021

33. Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study

Author

Delanoy, N, Robbrecht, Debbie, Eisenberger, M, Sartor, O, de Wit, Ronald, Mercier, F, Geffriaud-Ricouard, C, De Bono, J, Oudard, S, Delanoy, N, Robbrecht, Debbie, Eisenberger, M, Sartor, O, de Wit, Ronald, Mercier, F, Geffriaud-Ricouard, C, De Bono, J, and Oudard, S

Abstract

Background: In the PROSELICA phase III trial (NCT01308580), cabazitaxel 20 mg/m 2 (CABA20) was non-inferior to cabazitaxel 25 mg/m 2 (CABA25) in mCRPC patients previously treated with docetaxel (DOC). The present post hoc analysis evaluates how the type of progression at randomization affected outcomes. Methods: Progression type at randomization was defined as follows: PSA progression only (PSA-p; no radiological progression (RADIO-p), no pain), RADIO-p (±PSA-p, no pain), or pain progression (PAIN-p, ±PSA-p, ±RADIO-p). Relationships between progression type and overall survival (OS), radiological progression-free survival (rPFS), and PSA response (confirmed PSA decrease ≥ 50%) were analyzed. Results: All randomized patients (n = 1200) had received prior DOC, and 25.7% had received prior abiraterone or enzalutamide. Progression type at randomization was evaluable in 1075 patients (PSA-p = 24.4%, RADIO-p = 20.8%, PAIN-p = 54.8%). Pain progression was associated with clinical and biological features of aggressive disease. Median OS from CABA initiation or date of mCRPC diagnosis, all arms combined, was shorter in the PAIN-p group than in the RADIO-p or the PSA-p groups (12.0 versus 16.8 and 18.4 months, respectively, p < 0.001). In multivariate analysis, all arms combined, PAIN-p was an independent predictor of poor OS (HR = 1.44, p < 0.001). PSA response, rPFS, and OS were numerically higher with CABA25 versus CABA20 in patients with PAIN-p. Conclusions: This post hoc analysis of the PROSELICA phase III study shows that pain progression at initiation of CABA in mCRPC patients previously treated with DOC is associated with a poor prognosis. Disease progression should be carefully monitored, even in the absence of PSA rise.

Published
2021

34. 2364MO Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial

Author

Thibault, C., Bennamoun, M., Flechon, A., Gravis, G., Pouessel, D., Combe, P-F., Borchiellini, D., Loriot, Y., Laguerre, B., Barthelemy, P., Gross Goupil, M., Helissey, C., Huillard, O., Cancel, M., Campedel, L., Audenet, F., Belhouari, H., Kotti, S., Tran, Y., and Oudard, S.

Published
2023
Full Text
View/download PDF

36. 1839P Circulating tumor DNA (ctDNA) low pass whole genome sequencing (lpWGS) studies identify genomic alterations associating with taxane outcomes in prospective phase III taxane trials for metastatic castration resistant prostate cancer (mCRPC) sufferers

Author

Seed, G., Greening, S., Goodall, J., Rekowski, J., Christova, R., Mehra, N., Eisenberger, M., Fizazi, K., Tombal, B., Wülfing, C., Sternberg, C.N., Castellano Gauna, D.E., Oudard, S., Sartor, O., Geffriaud-Ricouard, C., Chadjaa, M., Mace, S., Carreira, S., Yuan, W., and de Bono, J.S.

Published
2023
Full Text
View/download PDF

37. 1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial

Author

Oudard, S., Ratta, R., Voog, E., Barthelemy, P., Thiery-Vuillemin, A., Bennamoun, M., Hasbini, A., Aldabbagh, K., Saldana, C., Von Amsberg, G., Houede, N., Besson, D., Feyerabend, S., Boegemann, M., Falcoz, A., Vernerey, D., Belhouari, H., Kotti, S., Tran, Y., and Helissey, C.

Published
2023
Full Text
View/download PDF

42. Erratum to ‘Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database’ [European Journal of Cancer, Volume 125 (January 2020) Pages 153–163] (European Journal of Cancer (2020) 125 (153–163), (S0959804919308020), (10.1016/j.ejca.2019.10.030))

Author

Delanoy, N. Hardy-Bessard, A.-C. Efstathiou, E. Moulec, S.L. Basso, U. Birtle, A. Thomson, A. Krainer, M. Guillot, A. Giorgi, U.D. Hasbini, A. Daugaard, G. Bahl, A. Chowdhury, S. Caffo, O. Beuzeboc, P. Spaeth, D. Eymard, J.-C. Fléchon, A. Alexandre, J. Helissey, C. Butt, M. Priou, F. Lechevallier, E. Deville, J.-L. Gross-Goupil, M. Morales, R. Thiery-Vuillemin, A. Gavrikova, T. Barthélémy, P. Sella, A. Fizazi, K. Ferrero, J.-M. Laguerre, B. Thibault, C. Hans, S. Oudard, S.

Abstract

The publisher regrets that the following corrections were missed during the publication of this article. Figure 2 legend is missing from the published article and should appear as follows: Figure 2: Overall survival from initiation of each life-extending therapy in accordance with the type of progression in 661 patients with mCRPC. (A) OS from first life-extending therapy (LET) initiation (all arms combined), (B) OS from second LET initiation (all arms combined), and (C) OS from third LET initiation (all arms combined). Referring to Table 3, ‘Median OS (all arms combined) in months’, the 1st LET entry for the Clin-p column should appear as 30.7 [27.5; 32.9]. Referring to Figure 2A, median Clin-p should appear as 30.7 [27.5; 32.9]. The correct Figure is included here The publisher would like to apologise for any inconvenience caused. [Figure presented] © 2020 Elsevier Ltd

Published
2020

45. Corrigendum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database' [Eur J Canc 125, (January 2020) 153–163] (European Journal of Cancer (2020) 125 (153–163), (S0959804919308020), (10.1016/j.ejca.2019.10.030))

Author

Delanoy, N. Hardy-Bessard, A.-C. Efstathiou, E. Le Moulec, S. Basso, U. Birtle, A. Thomson, A. Krainer, M. Guillot, A. De Giorgi, U. Hasbini, A. Daugaard, G. Bahl, A. Chowdhury, S. Caffo, O. Beuzeboc, P. Spaeth, D. Eymard, J.-C. Fléchon, A. Alexandre, J. Helissey, C. Butt, M. Priou, F. Lechevallier, E. Deville, J.-L. Gross-Goupil, M. Morales, R. Thiery-Vuillemin, A. Gavrikova, T. Barthélémy, P. Sella, A. Fizazi, K. Ferrero, J.-M. Laguerre, B. Thibault, C. Hans, S. Oudard, S.

Abstract

The authors regret that the affiliation details for Ugo De Giorgi were incomplete in the original publication. The full affiliation is k Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy The authors would like to apologise for any inconvenience caused. © 2020 Elsevier Ltd

Published
2020

46. Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT)

Author

Oudard, S., Hadaschik, Boris, Saad, Fred, Cella, David, Basch, Ethan, Mainwaring, Paul, Graff, J.N., Dibaj, Seyedeh S., Li, S., Brookman-May, S.D., De Porre, P., Trudeau, Jeremiah J., Small, E.J., and Smith, Mitchell R.

Subjects
Medizin
Published
2020

47. Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN

Author

Uemura, H., Lee, J. Y., Oudard, S., Hadaschik, Boris A., Saad, F., Cella, D., Basch, E., Graff, J. N., Dibaj, S., Li, S., Brookman-May, S. D., De Porre, P., Bevans, K., Trudeau, J., Smith, M. R., and Small, E. J.

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2020

49. 1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy

Author

Powles, T.B., primary, Assaf, Z.J., additional, Davarpanah, N., additional, Hussain, M., additional, Oudard, S., additional, Gschwend, J.E., additional, Albers, P., additional, Castellano, D., additional, Nishiyama, H., additional, Daneshmand, S., additional, Grivas, P., additional, Sharma, S., additional, Sethi, H., additional, Aleshin, A., additional, Zhang, J., additional, Degaonkar, V., additional, Bais, C., additional, Carter, C.A., additional, Bellmunt, J., additional, and Mariathasan, S., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results